US 11,986,536 B2
Compound for the sequestration of undesirable antibodies in a patient
Oskar Smrzka, Vienna (AT); and Bettina Wanko, Vienna (AT)
Assigned to ABLEVIA BIOTECH GMBH, Vienna (AT)
Filed by ABLEVIA BIOTECH GMBH, Vienna (AT)
Filed on Aug. 4, 2021, as Appl. No. 17/393,626.
Application 17/393,626 is a continuation of application No. 17/424,791, previously published as PCT/EP2020/058024, filed on Mar. 23, 2020.
Claims priority of application No. 19164784 (EP), filed on Mar. 23, 2019.
Prior Publication US 2021/0369856 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); A61K 38/00 (2006.01); A61K 47/64 (2017.01); C07K 5/04 (2006.01); C07K 7/06 (2006.01); C07K 16/18 (2006.01)
CPC A61K 47/6811 (2017.08) [A61K 47/643 (2017.08); A61K 47/644 (2017.08); C07K 5/04 (2013.01); C07K 7/06 (2013.01); A61K 38/00 (2013.01); C07K 16/18 (2013.01)] 15 Claims
 
1. A method of rapid, selective depletion of an antibody when the antibody has become undesirable in an individual, the method comprising the following steps:
(i) identifying at least one mimotope for which the antibody is specific;
(ii) administering a first pharmaceutical composition comprising the antibody to a human individual in need thereof; and
(iii) administering a second pharmaceutical composition to said individual, wherein the second pharmaceutical composition comprises at least one pharmaceutically acceptable excipient and a compound comprising
a biopolymer scaffold selected from the group consisting of a human albumin, a human transferrin, a human alpha1-globulin, a human alpha2-globulin, a human beta globulin, and a human haptoglobin, and at least
a first mimotope of said antibody, wherein the first mimotope has a sequence length of 6-13 amino acids and does not bind to any human leukocyte antigen (HLA) class I molecule, and
a second mimotope of said antibody, wherein the second mimotope has a sequence length of 6-13 amino acids and does not bind to any HLA class I molecule;
wherein each of the first and second mimotopes is covalently bound to the biopolymer scaffold; and
wherein the second pharmaceutical composition of step (iii) is non-immunogenic in the individual; and
wherein step (iii) is performed after step (ii), wherein step (iii) is performed when the antibody has become undesirable in the individual.